COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00116662
Recruitment Status : Completed
First Posted : July 1, 2005
Last Update Posted : February 19, 2007
Information provided by:
Graceway Pharmaceuticals, LLC

Brief Summary:

The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of three different strengths of resiquimod gel applied to common wart(s) three times a week for up to twelve weeks.

A second purpose is to evaluate the safety of the drug.

Condition or disease Intervention/treatment Phase
Warts Drug: Resiquimod Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 84 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Single
Primary Purpose: Treatment
Official Title: A Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times Per Week for up to 12 Weeks for the Treatment of Common Warts in Pediatric Subjects
Study Start Date : March 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Warts

Primary Outcome Measures :
  1. Clearance of treated common wart(s)

Secondary Outcome Measures :
  1. Partial clearance of treated common wart(s)
  2. Wart recurrence

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   3 Years to 11 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of common wart(s)
  • Ages between 3 to 11

Exclusion Criteria:

  • Other types of wart(s), ie. plantar
  • Currently participating in another clinical study
  • Chronic viral hepatitis B or C

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00116662

Layout table for location information
United States, Arkansas
Fayetteville, Arkansas, United States, 72703
Little Rock, Arkansas, United States, 72205
United States, Georgia
Newnan, Georgia, United States, 30263
United States, Illinois
Buffalo Grove, Illinois, United States, 60089
United States, Indiana
Lafayette, Indiana, United States, 47904
United States, Kansas
Wichita, Kansas, United States, 67207
United States, Massachusetts
Boston, Massachusetts, United States, 02114
United States, Missouri
St. Louis, Missouri, United States, 63110
United States, Utah
Layton, Utah, United States, 84041
United States, Vermont
Burlington, Vermont, United States, 05401
Sponsors and Collaborators
Graceway Pharmaceuticals, LLC
Layout table for additonal information Identifier: NCT00116662    
Other Study ID Numbers: 1534-RESI
First Posted: July 1, 2005    Key Record Dates
Last Update Posted: February 19, 2007
Last Verified: November 2006
Keywords provided by Graceway Pharmaceuticals, LLC:
Common Wart(s)
3M Pharmaceuticals
Additional relevant MeSH terms:
Layout table for MeSH terms
Papillomavirus Infections
DNA Virus Infections
Virus Diseases
Skin Diseases, Viral
Tumor Virus Infections
Skin Diseases, Infectious
Skin Diseases